No Data
Chengda Biological (688739.SH): The recombinant 15-valent human papillomavirus vaccine (E. coli) has entered the Phase II clinical trial.
On March 19, Gelonghui reported that Chengda Biotechnology (688739.SH) announced that its collaboration with Peking Kangleweishi Biotechnology Co., Ltd. (referred to as "Kangleweishi") on the development of recombinant 15-valent human papillomavirus vaccine (E. coli) (referred to as "this vaccine" or "15-valent HPV vaccine") has completed Phase I clinical trials and will commence Phase II clinical trials. The 15-valent HPV vaccine developed in collaboration with Kangleweishi is currently the highest valency HPV vaccine that has been approved for marketing or IND globally. This vaccine covers all high-risk types of HPV defined by IARC and can reduce cervical
Does Liaoning Chengda Biotechnology Co.,Ltd.'s (SHSE:688739) Weak Fundamentals Mean That The Market Could Correct Its Share Price?
Chengda Biology: Announcement of the 2024 Annual Results Report of Liaoning Chengda Biology Co., Ltd.
Announcement of the 2024 Annual Results Report of Liaoning Chengda Biology Co., Ltd.
Chengda Biological (688739.SH): Net income for 2024 is 0.33 billion yuan, a year-on-year decrease of 28.4%.
On February 25, Geelong Hui announced that Chengda Biotech (688739.SH) published its 2024 annual performance report. During this reporting period, the company achieved a revenue of 1,676.2411 million yuan, a year-on-year decrease of 4.22%; the net income attributable to the parent company's owners was 333.5851 million yuan, a year-on-year decrease of 28.40%; the net income attributable to the parent company's owners after deducting non-recurring gains and losses was 314.5358 million yuan, a year-on-year decrease of 23.75%. The slight decline in the company's revenue is mainly due to intense competition in the domestic human rabies vaccine market leading to decreased sales revenue, as well as the inactivation of the Japanese encephalitis vaccine.
Chengda Biology (688739.SH): Application for the production of the quadrivalent influenza virus split vaccine has been accepted for Pharmaceutical registration.
On January 24, Gelonghui reported that Chengda Bio (688739.SH) announced that its wholly-owned subsidiary, Chengda Biological (Benxi) Co., Ltd. (referred to as the "Benxi subsidiary"), has recently received the "Acceptance Notification" from the National Medical Products Administration for the registration application of the quadrivalent influenza virus split vaccine (referred to as "quadrivalent influenza vaccine") produced domestically. The quadrivalent influenza vaccine registered for production by the Benxi subsidiary has good safety and immunogenicity, and can stimulate the body to generate immunity Against Influenza, used to prevent influenza caused by vaccine-related strains of the influenza virus.
Liaoning Chengda Biotechnology Co.,Ltd.'s (SHSE:688739) On An Uptrend But Financial Prospects Look Pretty Weak: Is The Stock Overpriced?
